Swiss-based biopharmaceutical company Inthera Bioscience has completed a series A financing round led by Merck Ventures to raise Sfr10.5m ($10.53m).
Aglaia BioMedical Ventures, Novo Seeds and other private investors also participated in the round.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
US-based biotechnology company Sea Lane Biotechnologies has sold its entire antibody and engineered protein technology portfolio to i2 Pharmaceuticals, a biopharmaceutical company also based in the US.
The portfolio includes human antibody libraries, human b-cell derived antibodies and surrobodies, which enable facile creation of bispecific therapeutic agents from arrays of monospecific agents.
Chinese biotechnology company InventisBio has completed a series B venture financing round to raise $19m.
The proceeds will be used to advance the company’s product development through phase one clinical trials.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataRigel Pharmaceuticals intends to raise $40m in gross proceeds through a public offering of shares of its common stock.
The US-based pharmaceutical company intends to use the proceeds for general corporate purposes.
